Coebergh J W, Pastore G, Gatta G, Corazziari I, Kamps W
Dutch Childhood Leukaemia Study Group, PO Box 43515, 2504 AM, The Hague, The Netherlands.
Eur J Cancer. 2001 Apr;37(6):687-94. doi: 10.1016/s0959-8049(01)00013-2.
The aim of this study was to provide a comparative description of geographical variations and time trends in the population-based survival of European children with acute lymphoblastic leukaemia (ALL). Data on 13344 newly diagnosed children (0--14 years) with ALL were included in the EUROCARE study and were collected were collected by 34 population-based cancer registries (four comprising only childhood malignancies), operating in 17 countries (four in Scandinavia, two in Southern Europe, three in Eastern Europe, six in Continental Europe and two in the UK). Age-specific crude survival rates were estimated for boys and girls according to country for the period 1985--1989 and in adjusted form to attain comparability. Overall pooled and weighted rates were estimated as European standards. Children dead at diagnosis or diagnosed only through a death certificate were excluded. Geographical variation was also estimated by calculating the relative death rate with respect to the pooled overall European rate. After adjustment for age, gender and country, a Cox regression analysis was used to estimate time trends in survival. Survival was compared with that in the USA, Japan, Canada and Australia. During 1985--1989, the 1-year survival rate varied from 99 to 79%, the 5-year survival rate from over 80 to 56% (with the exception of Estonia; 34%; 95% confidence interval (CI) 20--52) among the various countries; the European weighted means were 90 (95% CI 87--93) and 72% (95% CI 69--75), respectively. Survival was particularly favourable in (south) Sweden, Finland, Germany and The Netherlands and rather unfavourable in Estonia and (surprisingly) France, where only 4% of its population was covered by the participating registries. Compared with the period 1978--1981, the hazard ratio for the period 1986--1989 decreased to 0.59 (95% CI 0.54--0.64) and -- in a smaller set of registries -- to 0.49 (0.45--0.55) for 1990-1992, an annual decrease in this rate of approximately 3.5%. During 1985--1989, the 5-year survival rates for European children were largely similar to those found in the USA, Canada and Australia, but markedly better than those in Japan. Higher survival rates were found for countries with 'good' access to centrally organised diagnostic and treatment facilities which stimulated 'aggressive' treatments according to a protocol. However, a subdivision according to risk profiles, e.g. according to the initial white blood cell count at diagnosis, could not be made and this might have explained partially the geographical differences in survival, because a positive association appeared between incidence at age 1--4 years and 5-year survival in most countries.
本研究旨在对欧洲急性淋巴细胞白血病(ALL)患儿基于人群的生存率的地理差异和时间趋势进行比较描述。欧洲癌症和治愈研究(EUROCARE)纳入了13344例新诊断的ALL患儿(0至14岁)的数据,这些数据由17个国家的34个基于人群的癌症登记处收集(其中4个仅包括儿童恶性肿瘤),这些国家包括北欧4个、南欧2个、东欧3个、欧洲大陆6个和英国2个。分别按国家估算了1985 - 1989年期间男孩和女孩的年龄别粗生存率,并进行了调整以实现可比性。总体汇总加权率作为欧洲标准进行估算。诊断时死亡或仅通过死亡证明确诊的儿童被排除在外。还通过计算相对于汇总的欧洲总体率的相对死亡率来估算地理差异。在对年龄、性别和国家进行调整后,使用Cox回归分析来估算生存率的时间趋势。并将生存率与美国、日本、加拿大和澳大利亚的生存率进行了比较。在1985 - 1989年期间,各国1年生存率从99%到79%不等,5年生存率从超过80%到56%不等(爱沙尼亚除外;为34%;95%置信区间(CI)为20 - 52);欧洲加权平均值分别为90%(95%CI 87 - 93)和72%(95%CI 69 - 75)。瑞典(南部)、芬兰、德国和荷兰的生存率特别好,而爱沙尼亚和(令人惊讶的是)法国的生存率则相当低,法国只有4%的人口由参与登记的机构覆盖。与1978 - 1981年期间相比,1986 - 1989年期间的风险比降至0.59(95%CI 0.54 - 0.64),在一组较小的登记处中,1990 - 1992年降至0.49(0.45 - 0.55),该比率每年下降约3.5%。在1985 - 1989年期间,欧洲儿童的5年生存率与美国、加拿大和澳大利亚的生存率大致相似,但明显优于日本。对于能够很好地获得集中组织的诊断和治疗设施从而根据方案进行“积极”治疗的国家,生存率较高。然而,无法根据风险特征进行细分,例如根据诊断时的初始白细胞计数进行细分,这可能部分解释了生存率的地理差异,因为在大多数国家,1 - 4岁的发病率与5年生存率之间存在正相关。